Novel neutralizing antibody assays for recombinant human hookworm Na-GST-1 vaccine
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Abstract
Necator Americanus, a human hookworm causes approximately 85% of
the global hookworm infections. Hookworm ingest hemoglobin
containing erythrocytes. Hemoglobin is further digested to Heme and
Globin by hookworm's gut enzymes. Iron-containing Heme is a potent
enzyme inhibitor and generates toxic reactive oxygen species which is
toxic to hookworms. Hookworm's gut enzyme Na-GST-1 (Necator
americanus Glutathione S-Transferase-1) has been hypothesized to
detoxify Heme. Na-GST-1 adjuvanted with Alhydrogel® is a new vaccine
which is currently under clinical development. Na-GST-1 has two active
sites, the ligand binding or Heme detoxification site (H-site) and the
catalytic active glutathione binding site (G-site). We have developed invitro neutralizing antibody assays (NAbA) to assess the neutralizing
capacity of antibodies against the functional activity of these two active
sites. The antibodies used in this assay were purified from serum of
BALB/c mice vaccinated with Na-GST-1 vaccine. Also, purified
antibodies from Brazilian volunteers plasma from the Na-GST-1 Phase 1
clinical trial was used to estimate the neutralizing capacity of antibodies.
Here, we report the development and results of these two novel in-vitro
assays.

Na-GST-1 Hookworm Vaccine

Necator americanus glutathione S-Transferase-1 (Na-GST-1) is a 24-kDa
protein from N. americanus. The recombinant polypeptide Na-GST-1 was
expressed in Pichia pastoris. Na-GST-1 Hookworm Vaccine Drug Product
was formulated at 0.1 mg/ml of Na-GST-1 on 0.8 mg/ml of Alhydrogel®
in 10mM Imidazole,10% Glucose (pH 7.4). The cGMP manufactured
vaccine was stored at 4° C.

NAbA based on neutralizing the enzymatic activity of Na-GST-1

This assay utilizes CDNB (1-Chloro-2,4-dinitrobenzene) a substrate which
evaluates the catalytic activity of Na-GST-1 in 0.1 M Potassium phosphate
(pH 6.5) buffer in presence of GSH (glutathione). To determine the
neutralizing capacity of antibodies against the enzymatic activity, the
purified IgG was incubated with the above components at 37°C for 60
min. The experimental steps for the assay are shown below,
Enzymatic Activity

†The

rate of increase in the absorption at 340nm is directly proportional to the GST Activity.

NAbA based on neutralizing the Hematin protective function of
Na-GST-1 (Iron releasing assay)

This assay utilizes hematin, H2O2 (oxidizer), Trichloroacetic acid (TCA),
Ascorbic Acid (reducing reagent) and Ferrozine (Iron detection reagent).
This assay estimates the Na-GST-1 activity by measuring the Iron release
from the Hematin using ferrozine reagent (iron detection reagent).
Oxidizer like H2O2 causes hematin degradation leading to the release of
free Iron. Na-GST-1 protects hematin from degradation and prevents the
release of free iron i.e. detoxification (parasite). Neutralizing this hematin
protective function of Na-GST-1 by neutralizing antibodies (IgG) will
eventually cause increase in the release of free iron from the degraded
hematin. In-vivo iron released from Heme can lead to toxicity and death
of hookworm. The experimental steps for this assay are as shown below,
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Figure 5. Neutralization of Hematin detoxification activity of
Na-GST-1 by Anti Na-GST-1 specific Human IgG
.

100 µM Hematin, 100 µM Protoporphyrin IX, 100µM Cytochrome C, 100µM Myoglobin,
50 µM ferrodoxin and 10 mM H2O2 and 50 µg Na-GST-1 was used in above assays.
† Iron detection reagent contains 0.04M ferrozine,0.1M ammonium acetate and 1M ascorbic
acid in water (pH 7.4).

Figure 2 Panel A, shows the hematin protective function of Na-GST-1.
Shown here by the decrease in release of free iron in presence of 50 µg of
Na-GST-1. Figure 2 Panel B, shows that the Na-GST-1 function is specific to
Hematin and does not have any effect on any other iron containing
molecule. A Mann–Whitney U test was used to statistically compare the
groups with a significance level α = 0.05.

cPurified

Anti Na-GST-1 specific Human IgG from Day 126 Plasma from Phase 1 Trial,

samples C5 BH025, C6 BH032, C6 BH036 (ODs >3.500 at 1:800 in an anti Na-GST-1 IgG ELISA)
dPurified Human IgG from commercial plasma and Non-Endemic (NE) human Plasma.
mAb anti-Sj-GST IgG = mouse monoclonal IgG against Sj-GST.

Figure 5, shows the Iron release from 250 µM Hematin when
incubated with 5 µg Na-GST-1 and 100mM H202 and IgG at 37°C.

Figure 3. Neutralization of Hematin† detoxification activity of
Na-GST-1 by mouse polyclonal IgG

Figure 6. Percent inhibition* at five different levels of

† Iron released from 300µM Hematin with 10µg Na-GST-1 and 10mM H202 and IgG at 37°C.
-IgG = Purified IgG from negative human plasma.
+IgG = Purified IgG from mice vaccinated with Na-GST-1.
mAb GST IgG = Mouse monoclonal Antibody (8-326) against 26kDa Recombinant full length GST
alpha (purified) (Pierce).
A Mann–Whitney U test was used to statistically compare the groups with a significance level
α = 0.05.

*ODs of Anti Na-GST-1 specific Human IgG with the remaining components compared
to the ODs of 250 µM Hematin with 5 µg Na-GST-1 and 100mM H202 at 37°C .
4PL fit= 4 Parameter Logistic Nonlinear Regression model

Anti Na-GST-1 specific Human IgG using 4PL fit.
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Study designs for the generation of antibodies
1. Balb/c Mouse Model
Ten BALB/c mice were immunized 50 µg Na-GST-1 + 400 µg Alhydrogel®
intraperitonealy using the following vaccination and bleed schedule.
Total as well as specific Na-GST-1 IgG was purified from the terminal
bleed serum as shown below.
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Figure 2. Na-GST-1 reduces iron-release from Hematin†
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Figure 1. Percent Inhibition of the enzymatic activity of Na-GST-1*
vs Purified Mouse Polyclonal IgG.

Figure 4. Neutralization of Hematin detoxification activity of
Na-GST-1 by Anti-Na-GST-1 specific mouse IgG.

Conclusion

• In-vitro assay showed that Na-GST-1 can prevent the release of free-iron
from hematin.
•Total IgG (micrograms) purified from Na-GST-1 vaccinated mice showed a
dose-dependent neutralizing capacity against the Na-GST-1 enzymatic activity
and Na-GST-1 hematin-detoxification activity.
•Anti Na-GST-1 specific IgG (nanograms) purified from the mouse model
showed a more sensitive (analytic) dose-dependent neutralizing capacity
against Na-GST-1 hematin-detoxification activity.

Anti Na-GST-1
specific IgG

2. Phase 1 Clinical Trial in Endemic Population (Brazil)
This study consisted of 6 cohort and each cohort containing 6
volunteers. Antibodies were purified from the study D126 plasma of the
six volunteers from one of the cohort. This cohort was vaccinated thrice
with 100 µg Na-GST-1 + 800 µg Alhydrogel® intramuscularly as shown
below.

•Anti Na-GST-1 specific IgG purified from Phase 1 Brazilian Adults showed a
dose dependent neutralizing capacity against Na-GST-1 heme-detoxification
activity. The hematin-detoxification activity of 5µg of Na-GST-1 was inhibited
by 50% using 5.04 ng of Anti Na-GST-1 specific human IgG.
•These neutralizing antibody assay results based on neutralizing the Hematin
protective function of Na-GST-1 can eventually generate an immune
correlates of protection using the samples from the Phase 2 Clinical Trial.
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of Positive IgG compared to ODs of Negative IgG (commercial mouse IgG)

Figure 1, shows the neutralizing capacity of 20µg, 15µg, 10µg and 5µg of
mouse polyclonal IgG with 500ng of Na-GST-1 in presence of 1mM GSH,
1mM CDNB in 0.1M KH2PO4 buffer (pH 6.5) at 37°C.

Anti Na-GST-1 specific mouse IgG.
mAb anti-Sj-GST IgG = mouse monoclonal IgG against Sj-GST.
Pos 1 is from Pierce and Pos 2 is from Sigma.
Mouse Negative = Commercial mouse negative IgG. NE = Non-Endemic Plasma.

b Purified

Figure 4, shows the iron released from 200µM Hematin when incubated
with 5µg Na-GST-1, 100mM H202 and IgG at 37°C
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